PLAAT3: A Target for Obesity and Metabolic Disorders (G11145)

Target Name: PLAAT3

NCBI ID: G11145

PLAAT3

PLAAT3: A Target for Obesity and Metabolic Disorders

PLAAT3 (Adipose-specific phospholipase A2) is a protein that is expressed in adipose tissue, which is the fatty tissue found beneath the skin and surrounding organs. It is a member of the AIMP (aspartate-specific intracellular phospholipase) family, which includes enzymes that regulate the internal phospholipid content of cells.

PLAAT3 is involved in the process of lipid metabolism, specifically the breakdown of triglycerides and the production of fatty acids. It is also involved in the regulation of cellular signaling pathways, including the production of signaling molecules such as nitric oxide.

One of the key functions of PLAAT3 is its role in the regulation of lipid metabolism during development and obesity. It has been shown to be involved in the regulation of lipid oxidation and the production of fatty acids, which are critical for the development and maintenance of obesity.

In addition to its role in lipid metabolism, PLAAT3 is also involved in the regulation of cellular signaling pathways. It is a potent inhibitor of the protein kinase CK5, which is involved in cell signaling. This means that when PLAAT3 is activated, it can inhibit the activity of CK5 and prevent the formation of cAMP, which is a key signaling molecule.

This lack of activity by PLAAT3 makes it an attractive drug target. Researchers are currently working to develop drugs that can specifically target PLAAT3 and inhibit its activity. These drugs have the potential to be used for a variety of therapeutic applications, including the treatment of obesity and other metabolic disorders.

In conclusion, PLAAT3 is a protein that is expressed in adipose tissue and is involved in the regulation of lipid metabolism and cellular signaling pathways. Its role in these processes makes it an attractive drug target for the development of new therapeutic applications. Further research is needed to fully understand the mechanisms of PLAAT3's activity and to develop safe and effective drugs that can target it.

Protein Name: Phospholipase A And Acyltransferase 3

Functions: Exhibits both phospholipase A1/2 and acyltransferase activities (PubMed:19615464, PubMed:19047760, PubMed:22825852, PubMed:22605381, PubMed:26503625). Shows phospholipase A1 (PLA1) and A2 (PLA2) activity, catalyzing the calcium-independent release of fatty acids from the sn-1 or sn-2 position of glycerophospholipids (PubMed:19615464, PubMed:19047760, PubMed:22825852, PubMed:22605381, PubMed:22923616). For most substrates, PLA1 activity is much higher than PLA2 activity (PubMed:19615464). Shows O-acyltransferase activity,catalyzing the transfer of a fatty acyl group from glycerophospholipid to the hydroxyl group of lysophospholipid (PubMed:19615464). Shows N-acyltransferase activity, catalyzing the calcium-independent transfer of a fatty acyl group at the sn-1 position of phosphatidylcholine (PC) and other glycerophospholipids to the primary amine of phosphatidylethanolamine (PE), forming N-acylphosphatidylethanolamine (NAPE), which serves as precursor for N-acylethanolamines (NAEs) (PubMed:19615464, PubMed:19047760, PubMed:22825852, PubMed:22605381). Exhibits high N-acyltransferase activity and low phospholipase A1/2 activity (PubMed:22825852). Required for complete organelle rupture and degradation that occur during eye lens terminal differentiation, when fiber cells that compose the lens degrade all membrane-bound organelles in order to provide lens with transparency to allow the passage of light. Organelle membrane degradation is probably catalyzed by the phospholipase activity (By similarity)

The "PLAAT3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLAAT3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets